<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Journal of Research in Orthopedic Science</title>
<title_fa>Journal of Research in Orthopedic Science</title_fa>
<short_title>JROS</short_title>
<subject>Medical Sciences</subject>
<web_url>http://jros.iums.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2676-7031</journal_id_issn>
<journal_id_issn_online>2676-7031</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.32598/JROSJ</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1401</year>
	<month>8</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2022</year>
	<month>11</month>
	<day>1</day>
</pubdate>
<volume>9</volume>
<number>4</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Survival Analysis of Osteosarcoma in a University Hospital in Yazd, Iran From 2004 to 2018: A Period Analysis</title>
	<subject_fa>تومور</subject_fa>
	<subject>Tumor surgery</subject>
	<content_type_fa>پژوهشی</content_type_fa>
	<content_type>Research Article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-size:14px;&quot;&gt;&lt;span style=&quot;font-family:Tahoma;&quot;&gt;&lt;span style=&quot;line-height:2;&quot;&gt;&lt;strong&gt;Background and Objectives&lt;/strong&gt;: Osteosarcoma (OS) is the most common cause of limb loss due to cancers. This study determines the mean survival time in patients with OS and prognostic factors.&lt;br&gt;
&lt;strong&gt;Methods&lt;/strong&gt;: This retrospective study was conducted on patients with OS who were referred to Shah Vali Hospital, Yazd, Iran, from 2004 to 2018. The data on patient-related factors (age and sex), tumor-related factors (recurrence, recurrence site, and metastasis), and living status were obtained and analyzed.&lt;br&gt;
&lt;strong&gt;Results&lt;/strong&gt;: Overall, 29 patients were included, of which 21(72.4%) were male. The mean age of patients was 21.3&amp;plusmn;8.4 (age range of 8-42) years. The tumor site was the lower limb in 23 patients (79.3%), the upper limbs in 4 patients (13.8%), and the axial in 2 patients (6.9%). Meanwhile, 13(44.8%) patients died due to OS, and one (6.9%) died for other reasons. The mean survival time in the subjects was 83.1&amp;plusmn;14.71 months. The 1-year survival of patients was nearly 90%, 3-year survival was about 64%, and 5-year survival was 40%. Also, 7(24.1%) patients had primary metastasis. The mean survival period was 22.25 months in patients with primary metastasis and 98.87 months in patients without primary metastasis (P=0.011). Among the patients, 15(51.7%) had a recurrence, of which 6(20.7%) were local, and 9(31%) were distant recurrences. The mean survival period after the recurrence of patients was 21.27&amp;plusmn;5.07 months.&lt;br&gt;
&lt;strong&gt;Conclusion&lt;/strong&gt;: The mean survival period, according to sex, age, recurrence, and recurrence site, was not significant; however, it was significant according to metastasis.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Osteosarcoma, Survival analysis, Survival, metastasis</keyword>
	<start_page>209</start_page>
	<end_page>218</end_page>
	<web_url>http://jros.iums.ac.ir/browse.php?a_code=A-10-1003-3&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Amir</first_name>
	<middle_name></middle_name>
	<last_name>Ebrahimzadeh Babaki</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>Amirebrahimzadeh13@gmail.com</email>
	<code>10031947532846006897</code>
	<orcid>10031947532846006897</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Orthopedic, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Fahimeh</first_name>
	<middle_name></middle_name>
	<last_name>Ebrahimzadeh Babaki</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>ebrahimzade.7369@gmail.com</email>
	<code>10031947532846006898</code>
	<orcid>0009-0004-4800-1448</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Hematology-Oncology, Ali-ebn-Abitaleb Faculty of Medicine, Yazd Branch, Islamic Azad University, Yazd, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Mohammad Reza</first_name>
	<middle_name></middle_name>
	<last_name>Mortazavizadeh</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>Mortazavizadeh@yahoo.com</email>
	<code>10031947532846006899</code>
	<orcid>10031947532846006899</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Hematology-Oncology, Ali-ebn-Abitaleb Faculty of Medicine, Yazd Branch, Islamic Azad University, Yazd, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
